A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma
Abstract Background Ovarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options. Results The methylation array data of 551 patients with ovarian...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Clinical Epigenetics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13148-018-0574-0 |
id |
doaj-926a04dd4d11439e9ec7aae3fcd420c5 |
---|---|
record_format |
Article |
spelling |
doaj-926a04dd4d11439e9ec7aae3fcd420c52020-11-24T23:55:58ZengBMCClinical Epigenetics1868-70751868-70832018-11-0110111010.1186/s13148-018-0574-0A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinomaWenna Guo0Liucun Zhu1Minghao Yu2Rui Zhu3Qihan Chen4Qiang Wang5State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversitySchool of Life Sciences, Shanghai UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversitySchool of Life Sciences, Shanghai UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityState Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing UniversityAbstract Background Ovarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options. Results The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan–Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers. Conclusions This five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance.http://link.springer.com/article/10.1186/s13148-018-0574-0BiomarkerDNA methylationOSCPrognosisRisk stratification |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Wenna Guo Liucun Zhu Minghao Yu Rui Zhu Qihan Chen Qiang Wang |
spellingShingle |
Wenna Guo Liucun Zhu Minghao Yu Rui Zhu Qihan Chen Qiang Wang A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma Clinical Epigenetics Biomarker DNA methylation OSC Prognosis Risk stratification |
author_facet |
Wenna Guo Liucun Zhu Minghao Yu Rui Zhu Qihan Chen Qiang Wang |
author_sort |
Wenna Guo |
title |
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma |
title_short |
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma |
title_full |
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma |
title_fullStr |
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma |
title_full_unstemmed |
A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma |
title_sort |
five-dna methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma |
publisher |
BMC |
series |
Clinical Epigenetics |
issn |
1868-7075 1868-7083 |
publishDate |
2018-11-01 |
description |
Abstract Background Ovarian cancer is the most fatal tumor of the female reproductive system and the fifth leading cause of cancer death among women in the USA. The prognosis is poor due to the lack of biomarkers for treatment options. Results The methylation array data of 551 patients with ovarian serous cystadenocarcinoma (OSC) in The Cancer Genome Atlas (TCGA) database were assessed in this study to explore the methylation biomarkers associated with prognosis and improve the prognosis of patients. These patients were divided into training (first two thirds) and validation datasets (remaining one third). A five-DNA methylation signature was found to be significantly associated with the overall survival of patients with OSC using the Cox regression analysis in the training dataset. The Kaplan–Meier analysis showed that the five-DNA methylation signature could significantly distinguish the high- and low-risk patients in both training and validation sets. The receiver operating characteristic (ROC) analysis further confirmed that the five-DNA methylation signature exhibited high sensitivity and specificity to predict the prognostic survival of patients. Also, the five-DNA methylation signature was not only applicable in patients of different ages, stages, histologic grade, and size of residual tumor after surgery but also more accurate in predicting OSC prognosis compared with known biomarkers. Conclusions This five-DNA methylation signature demonstrated the potential of being a novel independent prognostic indicator and served as an important tool for guiding the clinical treatment of OSC to improve outcome prediction and management for patients. Hence, the findings of this study might have potential clinical significance. |
topic |
Biomarker DNA methylation OSC Prognosis Risk stratification |
url |
http://link.springer.com/article/10.1186/s13148-018-0574-0 |
work_keys_str_mv |
AT wennaguo afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT liucunzhu afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT minghaoyu afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT ruizhu afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT qihanchen afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT qiangwang afivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT wennaguo fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT liucunzhu fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT minghaoyu fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT ruizhu fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT qihanchen fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma AT qiangwang fivednamethylationsignatureactasanovelprognosticbiomarkerinpatientswithovarianserouscystadenocarcinoma |
_version_ |
1725460373257060352 |